Phase II studies of mitozolomide in melanoma, lung and ovarian cancer.

Abstract

Seventy-seven patients were treated with oral mitozolomide to assess the activity of this drug in melanoma, lung and ovarian cancer. Partial responses were seen in five of 18 evaluable patients with small cell lung cancer (SCLC) and three of 20 with melanoma. No activity was apparent in non small cell lung or epithelial ovarian cancer. The major toxicity was myelosuppression which necessitated reduction in the initial dosage from 115 to 90 mg/m2. However, even at this dose level, unpredictable WHO grade 4 toxicity occurred in non-pretreated patients. Thrombocytopenia was more common than leucopenia and eight patients required platelet transfusion for spontaneous or tumour-related haemorrhage. Myelotoxicity was considered responsible for two deaths and was a significant contributory factor in a further three. Non-haematological toxicity was minor. Thus, despite demonstrable activity in SCLC and melanoma, unpredictable myelosuppression is likely to preclude further assessment in combination chemotherapy regimes in these tumours.

• Authors: M Harding, V Docherty, R Mackie, A Dorward, S Kaye
• Journal: European journal of cancer & clinical oncology (Eur J Cancer Clin Oncol) Vol. 25 Issue 5 Pg. 785-8 (May 1989) ISSN: 0277-5379 [Print] England
• PMID: 2544429 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antineoplastic Agents
• Nitrogen Mustard Compounds
• mitozolomide

Topics

• Adult
• Aged
• Antineoplastic Agents (adverse effects, therapeutic use)
• Bone Marrow (drug effects)
• Carcinoma, Non-Small-Cell Lung (drug therapy)
• Carcinoma, Small Cell (drug therapy)
• Drug Evaluation
• Female
• Humans
• Lung Neoplasms (drug therapy)
• Male
• Melanoma (drug therapy)
• Middle Aged
• Nitrogen Mustard Compounds (adverse effects, therapeutic use)
• Ovarian Neoplasms (drug therapy)